Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 2,339 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacokinetics and Pharmacodynamics Clear all
Completed Phase 2 Interventional Results available

Dose Ranging of GSK2336805 in Combination Therapy

NCT01648140
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a, Ribavirin, Telaprevir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
18
States / cities
Dothan, Alabama • Anaheim, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Danavorexton in Anesthetized Adults

NCT05025397
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Danavorexton, Danavorexton Placebo, Propofol, Sevoflurane
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 1 Interventional

Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes

NCT01544881
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Technosphere Insulin Inhalation Powder, Rapid Acting Analog
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis

NCT00147329
View directory record Official record
Conditions
Psoriasis
Interventions
MM-093
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Dallas, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 23, 2007 · Synced Oct 15, 2026, 4:22 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate CAY001 in Healthy Volunteers

NCT06845839
View directory record Official record
Conditions
Healthy
Interventions
CAY001, Placebo
Drug · Other
Lead sponsor
Cayuga Biotech, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Ascending Dose Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Volunteers.

NCT01995383
View directory record Official record
Conditions
Atherosclerosis
Interventions
LS followed by NS diet condition, NS followed by LS diet condition, Placebo, RO6836191
Other · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3209590 in Participants With Type 2 Diabetes

NCT03367377
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY3209590, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
South Miami, Florida • High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 15, 2026, 4:22 PM EDT
Active, not recruiting Phase 1 Interventional

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

NCT04446351
View directory record Official record
Conditions
Neoplasms
Interventions
GSK6097608, Dostarlimab, Cobolimab, Belrestotug
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 15, 2026, 4:22 PM EDT
Active, not recruiting Phase 1 Interventional

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

NCT05653882
View directory record Official record
Conditions
Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma
Interventions
etakafusp alfa (AB248), pembrolizumab
Biological
Lead sponsor
Asher Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
20
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

NCT01531673
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-661, Ivacaftor, Placebo matched to VX-661, Placebo matched to ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
19
States / cities
Birmingham, Alabama • Oakland, California • Boise, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis

NCT03334851
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Interventions
PF-06835375, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
17
States / cities
Anniston, Alabama • Beverly Hills, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 15, 2026, 4:22 PM EDT
Terminated Phase 1 Interventional Results available

LIONS (PLK4 Inhibitor in Advanced Solid Tumors)

NCT06232408
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
RP-1664
Drug
Lead sponsor
Repare Therapeutics
Industry
Eligibility
12 Years to 100 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
San Francisco, California • New Haven, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 2 Interventional

Study In People With Type 2 Diabetes

NCT00196989
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone, GW677954
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
69
States / cities
Birmingham, Alabama • Northport, Alabama • Chandler, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 15, 2026, 4:22 PM EDT
Recruiting Phase 1 Interventional

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia

NCT06366789
View directory record Official record
Conditions
AML With Gene Mutations
Interventions
ZE46-0134
Drug
Lead sponsor
Lomond Therapeutics Holdings, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers

NCT01292174
View directory record Official record
Conditions
Prevention of Infection With HIV-1
Interventions
ibalizumab (biologic/MAb) for SC Injection or placebo
Biological
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Long Beach, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 15, 2026, 4:22 PM EDT
Terminated Phase 1Phase 2 Interventional

A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency

NCT05154890
View directory record Official record
Conditions
Homocystinuria Due to Cystathionine Beta-Synthase Deficiency
Interventions
Pegtarviliase IV, Pegtarviliase SC
Drug
Lead sponsor
Aeglea Biotherapeutics
Industry
Eligibility
12 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015)

NCT02927210
View directory record Official record
Conditions
Healthy Men, Male Contraception
Interventions
Dimethandrolone Undecanoate, Placebo
Drug
Lead sponsor
Kimberly Myer
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 1 Interventional

Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency

NCT03815396
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency, AATD
Interventions
INBRX-101/rhAAT-Fc
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Sacramento, California • Gainesville, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Trial to Investigate the Safety and Tolerability of PF-06412562

NCT01914796
View directory record Official record
Conditions
Healthy
Interventions
PF-06412562
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

NCT03392896
View directory record Official record
Conditions
Primary Hyperoxaluria
Interventions
DCR-PHXC, Placebo
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
6 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects

NCT02460146
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
CXA-10, CXA-10 placebo
Drug · Other
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 15, 2026, 4:22 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

NCT06546670
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
ITU512, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 55 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
9
States / cities
Birmingham, Alabama • Miami, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

GSK2982772 Study in Subjects With Ulcerative Colitis

NCT02903966
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
GSK2982772, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Moreno Valley, California • San Diego, California • Marrero, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study of HU6 in High BMI Volunteers

NCT04709913
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
HU6
Drug
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 15, 2026, 4:22 PM EDT